OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Saltman on the Use of the DetermaIO Assay to Inform Immunotherapy Use in Advanced-Stage NSCLC

December 19th 2022

David L. Saltman, MD, PhD, discusses the use of the 27-gene Determa immuno-oncology assay to inform use of single-agent immunotherapy in patients with advanced-stage non–small cell lung cancer.

Dr. Sauter on Pembrolizumab After Stem Cell Transplant in T-Cell NHL

December 19th 2022

Craig Sauter, MD, discusses the investigation of pembrolizumab given after stem cell transplant in T-cell non-Hodgkin lymphoma.

Dr. Leslie on the 3-Year Follow-Up of the ZUMA-5 Trial in R/R iNHL

December 19th 2022

Lori A. Leslie, MD, discusses the 3-year follow-up data of the phase 2 ZUMA-5 trial in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Dr. Mian on the Investigation into the Synchronous Up-front Setting of Metastatic Prostate Cancer

December 19th 2022

Omar Mian, MD, PhD, discusses the ongoing investigation into the synchronous up-front setting of metastatic prostate cancer.

Dr. Contreras on Neoadjuvant Therapies in Basal Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

December 19th 2022

Carlo Contreras, MD, discusses areas of planned and ongoing research with neoadjuvant therapies in basal cell carcinoma and cutaneous squamous cell carcinoma.

Dr. Rimel on the Importance of BRCA and HRD Testing in Ovarian Cancer

December 19th 2022

Bobbie J. Rimel, MD, discusses the importance of testing patients with ovarian cancer for homologous recombination deficiency (HRD) or homologous recombination proficiency (HRP), and BRCA mutation status.

Dr. Cheah on the Investigation of BGB-11417 With or Without Zanubrutinib in CLL

December 16th 2022

Chan Cheah, MBBS, discusses the investigation of BGB-11417 with or without zanubrutinib in chronic lymphocytic leukemia.

Dr. Aggarwal on Treating Patients With EGFR Mutations in NSCLC

December 15th 2022

Charu Aggarwal, MD, MPH, discusses treating patients with EGFR-mutant non–small cell lung cancer.

Dr. George on the Clinical Benefit of Phenotypic Evaluation in Prostate Cancer

December 15th 2022

Daniel J. George, MD, discusses the clinical benefits of evaluating phenotype in metastatic castration-resistant prostate cancer.

Dr. Pakkala on Integrating Local Therapy into HER2+ Breast Cancer Treatment

December 15th 2022

Suchita Pakkala, MD, discusses ongoing efforts to integrate local therapy into HER2-positive breast cancer treatment.

Dr. Mercado on the Effect of the COVID-19 Pandemic on Lung Cancer Screening

December 14th 2022

Jorge M. Mercado, MD, discusses the effect of the COVID-19 pandemic on lung cancer screening.

Dr. Susanibar on Important Considerations When Treating Multiple Myeloma

December 14th 2022

Sandra P. Susanibar-Adaniya, MD, discusses important considerations when treating patients with multiple myeloma.

Dr. George on the Importance of Understanding Mutations in Prostate Cancer

December 14th 2022

Daniel J. George, MD, discusses the importance of understanding mutations in prostate cancer.

Dr. Jim on Real-World Quality of Life Outcomes With Axi-Cel in R/R LBCL

December 14th 2022

Heather Jim, PhD, discusses a real-world analysis, examining the quality of life outcomes seen with axicabtagene ciloleucel in patients with relapsed/refractory large B-cell lymphoma.

Dr. Singal on the FDA Approval of Durvalumab With Tremelimumab in Unresectable HCC

December 13th 2022

Amit Singal, MD, discusses the FDA approval of durvalumab with tremelimumab (Imjudo) in unresectable hepatocellular carcinoma.

Dr Reshef on Data From the BMT CTN 1703 Trial Evaluating Post-Transplant GVHD Prophylactic Regimens

December 13th 2022

Ran Reshef, MD, discusses findings from the phase 3 BMT CTN 1703 trial examining graft-vs-host disease prophylaxis in reduced intensity conditioning.

Dr Peffault de Latour on the Benefit of Iptacopan Vs SOC in PNH and Residual Anemia

December 13th 2022

Regis Peffault de Latour, MD, PhD, discusses the benefit observed with iptacopan vs standard-of-care eculizumab or ravulizumab in patients with paroxysmal nocturnal hemoglobinuria and residual anemia during the phase 3 APPLY-PNH trial.

Dr Topp on the Efficacy of Glofitamab Plus R-CHOP in Previously Untreated DLBCL

December 12th 2022

Max S. Topp, MD, discusses the efficacy of the combination of glofitamab plus R-CHOP from a phase 1 trial done in previously untreated patients with diffuse large B-cell lymphoma.

Dr. Spira on the FDA Approval of Adagrasib in KRAS G12C–mutant NSCLC

December 12th 2022

Alexander I. Spira, MD, PhD, FACP, discusses the FDA approval of adagrasib in patients with KRAS G12C–mutated non–small cell lung cancer.

Dr Abramson on the Efficacy of Second-line Liso-cel Vs SOC in Relapsed/Refractory LBCL

December 12th 2022

Jeremy Abramson, MD, discusses the efficacy data of second-line lisocabtagene maraleucel vs standard-of-care salvage chemotherapy followed by autologous stem cell transplant from the phase 3 TRANSFORM trial done in patients with relapsed/refractory large B-cell lymphoma.